同样纠的第81号:皮里多斯提格 (mestinon®)
Nadia Mansoor1, Terry Heiman-Patterson1, Eva L Feldman2,3
1Neurology Department, Temple University, Philadelphia, PA, USA.
Amyotrophic lateral sclerosis & frontotemporal degeneration
|November 6, 2025
概括
皮里多斯提格不会减缓肌缩侧面硬化症 (ALS) 的进展. 这种增强神经肌肉传播的药物缺乏修改ALS病理生理学的明确机制,并且在ALS患者的临床试验中没有显示出有效性.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经肌肉结位功能障碍是肌缩侧面硬化症 (ALS) 的早期特征.
- 皮里多斯提格明可以增强乙胆的可用性,从而有可能改善ALS的神经肌肉传播.
- 改变神经肌肉传播在ALS进展中的作用仍然不确定.
研究的目的:
- 评估皮里多斯提格在减缓ALS进展方面的潜力.
- 评估pyridostigmine在ALS中的疗效的机理性可信性.
- 审查针对ALS治疗抗胆化酶剂的现有临床证据.
主要方法:
- 关于ALS中神经肌肉结位功能障碍的临床前发现的综述.
- 分析了pyridostigmine在ALS中提出的作用机制.
- 对ALS患者的pyridostigmine和类似药物的临床试验数据的检查.
主要成果:
- 皮里多斯提格缺乏合理的机制来修改ALS病理生理学,而不仅仅是暂时的神经肌肉传输增强.
- 阳性乙胆受体自身抗体的ALS (PALS) 患者没有严重骨髓灰质炎症状,不太可能受益.
- 涉及类似抗胆酶剂的临床试验没有证明ALS进展的减缓.
结论:
- 由于缺乏机理学依据和已证明的疗效,皮里多斯蒂格明不支持用于减缓ALS进展.
- 常见的副作用包括肌肉性胆固醇症状,特别是胃肠道问题.
- 根据当前的证据,对ALS的pyridostigmine进行进一步的临床研究是不必要的.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
14.2K
07:09Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
Published on: September 8, 2011
14.0K
相关概念视频
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
896
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
896
01:26Cholinergic Antagonists: Therapeutic Uses
1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.5K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.5K
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.0K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K